Furthermore, AKR1C3 which functions as a prostaglandin F (PGF) synthase as well as its isoforms PGF2α and 11β-PGF2α are reported to induce prostate cancer development by preventing the activation of peroxisome proliferator-activated receptor gamma (PPARγ) [98]. Here, PPARG is linked to prostate carcinoma.